Low/Intermediate-Risk APL with WBC ≤10,000/ml: What Comes After Induction
Patients with acute promyelocytic leukemia (APL) and a white blood cell count at or below 10,000/ml are classified as low/intermediate-risk. After completing induction, a specific consolidation protocol governs the next treatment phase for this group.
Risk Stratification
WBC at or below 10,000/ml defines low/intermediate-risk APL. Most clinicians today use two categories — low/intermediate risk (WBC ≤10,000/ml) and high risk (WBC >10,000/ml) — to guide treatment selection.
After Induction with ATRA/ATO
Induction with ATRA/ATO (all-trans retinoic acid combined with arsenic trioxide) targets hematologic normalization, molecular clearance of PML-RARA, and resolution of coagulopathy. When induction concludes and those goals have not yet been fully confirmed, consolidation is the defined next step for this risk group.
Consolidation Approach
For low/intermediate-risk APL, the consolidation strategy is chemotherapy-free — a meaningful distinction from older regimens. The complete regimen and sequencing are set out in the full structured protocol.
Treatment Goal
The primary endpoint is PML-RARA negativity confirmed by PCR at the completion of consolidation.
References
DOI: 10.3389/fonc.2022.1062524
In the era of ATRA, APL has been stratified into three categories of risk with regards to relapse-free survival (RFS): WBC >10,000/ml (high-risk), WBC ≤10,000 ml with platelet count ≤40,000/ml (intermediate-risk), and WBC ≤10,000/ml with platelet count >40,000/ml (low-risk).
Today, most clinicians will categorize APL within two categories, high risk (>10,000/ml) and low/intermediate risk.
It is now known that low/intermediate-risk patients achieve excellent outcomes with chemotherapy-free ATRA/ATO-based consolidation following ATRA/ATO-based induction, and that high-risk patients who are successfully induced with ATRA/ATO with an anthracycline can be consolidated with ATRA/ATO with the omission of chemotherapy.
View source ↗